Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis
| Autor: | Nesrin Ugras, Sibel Kahraman Çetintaş, Gonca Özgün, Gokhan Ocakoglu, Muhammed Sadık Bilgen, Adem Deligonul, Ulviye Yalcinkaya |
|---|---|
| Přispěvatelé: | Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Patoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Ortopedi Anabilim Dalı., Yalçınkaya, Ulviye, Uğraş, Nesrin, Ocakoğlu, Gökhan, Deligönül, Adem, Çetintaş, Sbel Kahraman, Bilgen, Muhammed Sadık, AAH-5180-2021, AAA-7047-2020, AAH-8924-2021, AAH-2716-2021 |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Pathology Necrosis Proliferation Adolescents Cancer staging Metastasis 0302 clinical medicine Enhancer of zeste homologue 2 (EZH2) Multicenter Middle aged Disease free survival Children Cancer Sarcoma synovial Gene expression regulation lcsh:R5-920 Tumor Progression Synovial Sarcoma Mucin-1 EZH2 General Medicine Prognosis Immunohistochemistry Synovial sarcoma Gene Expression Regulation Neoplastic Retrospective study Blood Enhancer of zeste homolog 2 protein 030220 oncology & carcinogenesis Soft-tissue Ssx-fusion-type Female Sarcoma medicine.symptom lcsh:Medicine (General) Research Article Human Risk Adult medicine.medical_specialty Adolescent Disease-free survival Retrospective analysis Neoplasm metastasis Research & experimental medicine Predictive value macromolecular substances Prognostic factors Biosynthesis 03 medical and health sciences medicine Biomarkers Tumor Genetics Humans Predictive value of tests Tumor marker Medicine research & experimental Survival analysis Neoplastic business.industry Kaplan-meier estimate medicine.disease Transcription factor EZH2 Retrospective studies 030104 developmental biology Young adult Neoplasm staging EZH2 protein human Kaplan meier method business Immunostaining Biomarkers |
| Zdroj: | Bosnian Journal of Basic Medical Sciences, Vol 17, Iss 4 (2017) |
| Popis: | Synovial sarcoma (SS) is a type of soft-tissue sarcoma, often linked to poor survival. Although overexpression of enhancer of zeste homologue 2 (EZH2) has been associated with poor prognosis in different tumors, a few studies investigated this link in SS. Here, we analyzed the relationship between EZH2 expression and prognostic factors in SS. We included 29 patients with SS. Immunostaining of EZH2 was performed with (D2C9) XPTM Rabbit mAb antibody, and the results were classified as low EZH2 expression (negative or weak expression) and high EZH2 expression category (moderate or strong expression). Analysis of survival in relation to prognostic factors was performed with Kaplan-Meier survival curves and Cox proportional hazard regression analysis. Our sample included 19/29 female and 10/29 male patients, with age range 16-63 years. The tumor diameter ranged from 2 to 15 cm. Necrosis was observed in 15/29 cases. Sixteen cases had >10 mitoses per 50 high-power fields (HPFs). Out of 29 cases, 14 showed low and 15 had high EZH2 expression. Statistically significant results were obtained for the association between the presence of metastasis and necrosis (p = 0.042), high EZH2 expression and distant metastasis (p = 0.018), high EZH2 expression and necrosis (p = 0.016), and high EZH2 expression and the tumor size >5 cm versus tumor size ≤5 cm (p = 0.014). Patients with all of the following: the tumor size ≤5 cm, low EZH2 expression, and without necrosis and distant metastasis had significantly longer survival time. Our results are consistent with previous studies, suggesting that EZH2 overexpression is an indicator of poor prognosis in SS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|